Results 101 to 110 of about 2,979 (199)
Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy [PDF]
, 2013 Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist in late-stage clinical development for the treatment of bipolar disorder (manic/mixed and depressive episodes), as well as for schizophrenia, and as an adjunctive agent for the ...
Citrome, Leslie, Leslie Citrome
core +1 more source
Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults
, 2020 Purpose of Review: Antipsychotics are the standard of care when it comes to the treatment of Schizophrenia, and they are often used in Bipolar as well. Their use can come with adverse effects such as extrapyramidal movements, metabolic complications as ...
Kaye, Adam M. +9 more
core
Comparative effectiveness and safety of cariprazine and lamotrigine in patients of bipolar depression: a prospective, randomized and open label study [PDF]
Background: Bipolar disorder is marked by significant shifts in mood, energy, and behaviour. Cariprazine, a D3/D2 (dopamine) partial agonist, was FDA-approved in 2019 for treating bipolar depression, though clinical trial results have been mixed.
Sharma, Sankasha +2 more
core +1 more source
Cariprazine in Bipolar Depression and Mania: State of the Art.
, 2018 BACKGROUND & OBJECTIVE: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A
Janiri L +3 more
core +1 more source
European PsychiatryIntroduction Several studies have demonstrated the unfavorable and neurotoxic effects of untreated psychosis (UP) on the brain. An estimated 10 to 12 cc of brain tissue could be potentially damaged due to neuroinflammation and oxidative stress when a ...
A. Mara, S. Myriknas
doaj +1 more source
A 12-month longitudinal naturalistic follow-up of cariprazine in schizophrenia [PDF]
Background Cariprazine, a third-generation antipsychotic (TGAs), has demonstrated efficacy in the treatment of schizophrenia with good tolerability profile.
Dell'Oste V. +6 more
core +1 more source
Indian Journal of Psychological MedicineCariprazine is one of the newer generation antipsychotics with dopamine receptor partial agonist activity which has been approved for management of schizophrenia and bipolar affective disorder.
Devendra Singh Basera +3 more
doaj +1 more source
D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside
Until the late 1800s, drug development was a chance finding based on observations and repeated trials and errors. Today, drug development must go through many iterations and tests to ensure it is safe, potent, and effective.
György Németh +2 more
core +1 more source
, 2010 ObjectivesTo evaluate the striatal D3/D2 receptor occupancy of cariprazine (RGH-188) in healthy volunteers and schizophrenic patients, and assess the correlation between cariprazine plasma concentration and receptor occupancy.MethodsSingle- (0.5 mg) or ...
A. Gage +3 more
core +1 more source
Introduction: Metabolic adverse effects are a major concern during long-term antipsychotic treatment because they contribute to cardiovascular complications, endocrine disturbances, and reduced treatment adherence.
Klaudia Magdalena Kotlarska +7 more
core +1 more source